Pasar al contenido principal

REDUCCION DEL TIEMPO DE DESARROLLO DE ANTIVIRALES ORALES MEDIANTE OPTIMIZACION IN VITRO DE FORMULACIONES: MEDICINAS RAPIDAS, SEGURAS Y BIOEQUIVALENTES.

PID2021-123888OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Pharmaceutical Compounding in Veterinary Medicine: Suspension of Itraconazole

  • Cabañero-Resta, Gema J.
  • Sánchez-Dengra, Bárbara
  • Ruiz Picazo, Alejandro
  • Bermejo, Marival
  • Merino Sanjuan, Virginia
  • González-Álvarez, Isabel
  • González-Álvarez, Marta
[EN] Itraconazole is a drug used in veterinary medicine for the treatment of different varieties of dermatophytosis at doses between 3-5 mg/kg/day in cats. Nevertheless, in Spain, it is only available in the market as a 52 mL suspension at 10 mg/mL. The lack of alternative formulations, which provide sufficient formulation to cover the treatment of large animals or allow the treatment of a group of them, can be overcome with compounding. For this purpose, it has to be considered that itraconazole is a weak base, class II compound, according to the Biopharmaceutics Classification System, that can precipitate when reaching the duodenum. The aim of this work is to develop alternative oral formulations of itraconazole for the treatment of dermatophytosis. Several oral compounds of itraconazole were prepared and compared, in terms of dissolution rate, permeability, and stability, in order to provide alternatives to the medicine commercialized. The most promising formulation contained hydroxypropyl methylcellulose and beta-cyclodextrin. This combination of excipients was capable of dissolving the same concentration as the reference product and delaying the precipitation of itraconazole upon leaving the stomach. Moreover, the intestinal permeability of itraconazole was increased more than two-fold., The authors acknowledge partial financial support to the projects. This work was supported by grants: CIAICO/2022/082, funded by GVA Conselleria de Educación Universidades y Empleo, and PID2021-123888OB-I00, funded by MCIN/AEI/10.13039/501100011033/FEDER, UE.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Intranasal administration of molecular-gated mesoporous nanoparticles to increase ponatinib delivery to the brain

  • Sánchez-Dengra, Barbara
  • Alfonso, María
  • Gonzalez-Alvarez, Isabel
  • Bermejo, Marival
  • Gonzalez -Alvarez, Marta
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Background: Glioblastoma is the most common and lethal brain cancer. New treatments are needed. However, the presence of the blood-brain barrier is limiting the development of new treatments directed toward the brain, as it restricts the access and distribution of drugs to the CNS. Materials & methods: In this work, two different nanoparticles (i.e., mesoporous silica nanoparticles and magnetic mesoporous silica nanoparticles) loaded with ponatinib were prepared. Results & conclusion: Both particles were characterized and tested in vitro and in vivo, proving that they are not toxic for blood-brain barrier cells and they increase the amount of drug reaching the brain when administered intranasally in comparison with the results obtained for the free drug., This work was supported, in part, by the project "NUEVA FORMULACION DE PONATINIB PARA EL TRATAMIENTO DEL GLIOMA" funded by FUNDACION BIENVENIDA NAVARRO-LUCIANO TRIPODI and, in part, by the project [PID2021-123888OB-100] funded by Ministry of Science and Innovation from Spain. B Sanchez-Dengra received a grant from the Ministry of Science, Innovation and Universities of Spain (FPU17/00530) and a complementary grant from the Ministry of Science, Innovation and Universities of Spain (EST19/00010).